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Abstract: The anti-inflammatory and anticancer properties of eight meroterpenoids isolated from 
the brown seaweed Cystoseira usneoides have been evaluated. The algal meroterpenoids (AMTs) 1–8 
were tested for their inhibitory effects on the production of the pro-inflammatory cytokines tumor 
necrosis factor (TNF-α), interleukin-6 (IL-6), and interleukin-1β (IL-1β), and the expression of 
cyclooxygenase-2 (COX-2), and inducible nitric oxide synthase (iNOS) in LPS-stimulated THP-1 
human macrophages. The anticancer effects were assessed by cytotoxicity assays against human 
lung adenocarcinoma A549 cells and normal lung fibroblastic MRC-5 cells, together with flow 
cytometry analysis of the effects of these AMTs on different phases of the cell cycle. The AMTs 1–8 
significantly reduced the production of TNF-α, IL-6, and IL-1β, and suppressed the COX-2 and 
iNOS expression, in LPS-stimulated cells (p < 0.05). The AMTs 1–8 displayed higher cytotoxic 
activities against A549 cancer cells than against MRC-5 normal lung cells. Cell cycle analyses 
indicated that most of the AMTs caused the arrest of A549 cells at the G2/M and S phases. The 
AMTs 2 and 5 stand out by combining significant anti-inflammatory and anticancer activities, 
while 3 and 4 showed interesting selective anticancer effects. These findings suggest that the AMTs 
produced by C. usneoides may have therapeutic potential in inflammatory diseases and lung cancer. 
Keywords: meroterpenoids; Cystoseira usneoides; inflammation; cytokines; lung cancer; cell cycle 
 
1. Introduction 
Inflammation is a physiologic process in response to invading pathogens or endogenous signals 
such as tissue injury. It is initiated by migration of immune cells from blood vessels and release of 
mediators, followed by recruitment of inflammatory cells and secretion of increased amounts of 
cytokines and chemokines to eliminate invading pathogens and to repair damaged tissues [1–3]. 
During the past decade, numerous epidemiological studies have consistently linked the 
immune system with tumorigenesis [4]. However, the role of inflammation in cancer is not new. 
Virchow postulated in 1863 that tumors arise in areas of chronic inflammation and that 
inflammation cells were present in the resected tumors [5,6]. These observations led him to 
hypothesize that inflammation is a predisposing factor of carcinogenesis [3,6]. It is now becoming 
clear that the immune system contributes to all stages of tumorigenesis, from initiation to invasion 
and metastasis of tumors, by providing abundant molecules to the tumor microenvironment. These 
molecules include growth factors, cytokines, and chemokines that increase mutagenesis, promote 
unregulated cell proliferation, limit apoptosis, and favor angiogenesis, invasion, and metastasis 
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[4,7]. Nevertheless, the role of the immune system during carcinogenesis is complex, dynamic and 
ambivalent, and is now known to have the potential to both promote and revoke carcinogenic 
response [8–10]. 
Lung cancer causes 19% of all cancer deaths worldwide [11]; it is the most commonly diagnosed 
cancer and the leading cause of cancer-related mortality both in males and females [12,13]. The lung, 
as an organ of the respiratory system exposed to the outer environment, is a place predisposed for 
infections and chronic inflammatory injuries [14,15]. The chronic airway inflammation contributes to 
DNA damage, mutation, and pathological/molecular alterations in the bronchial epithelium and 
microenvironment, through the production of different cytokines, chemokines, and transcription 
factor networks, which increase lung tumor development and progression [14–16]. Hence, a strategy 
for the prevention and treatment of lung cancer could involve the regulation of inflammatory 
molecules, including pro-inflammatory cytokines, and inflammatory enzymes, such as 
cyclooxygenase-2 (COX-2) and inducible nitric oxide synthetase (iNOS) [17,18]. 
Since ancient times to nowadays, seaweeds have been used for food and diverse consumer 
products, due to their low content in lipids and high concentration in vitamins, minerals, proteins, 
dietary fiber, and polysaccharides [19–21]. In addition, a variety of metabolites from macroalgae 
have been shown to possess health promoting effects, including antioxidant [22], anti-inflammatory 
[23], antimicrobial [24], and antitumor [25] properties. Brown algae are a promising group of 
seaweeds known to be a rich source of bioactive compounds [26]. Among brown algae, the genus 
Cystoseira, which currently encompasses about 50 species distributed throughout the northeastern 
Atlantic Ocean and the Mediterranean Sea [27], has been widely studied, from both chemical and 
biological points of view [28]. In particular, many algae of the genus Cystoseira have been described 
to contain a variety of natural products of the meroditerpene class [28–31] some of which have been 
shown to possess anticancer and anti-inflammatory properties [28,29,32]. 
Hence, the current research has been aimed at expanding our investigation over the 
anti-inflammatory and anticancer effects of the algal meroterpenoids (AMTs) 1–8 previously isolated 
from the species C. usneoides [33]. Herein, we demonstrate that the AMTs 1–8 exhibit 
anti-inflammatory activities through the inhibition of pro-inflammatory cytokines (TNF-α, IL-6, and 
IL-1β), the protein expressions of COX-2 and iNOS in the LPS-stimulated THP-1 human 
macrophages, as well as that the AMTs 1–8 possess selective anticancer activity against human lung 
cancer cells A549 by inducing cell cycle arrest. 
2. Results 
The algal meroterpenoids (AMTs) usneoidone Z (1), 11-hydroxy-1’-O-methylamentadione (2), 
cystomexicone B (3), cystomexicone A (4), 6-cis-amentadione-1′-methyl ether (5), 
amentadione-1′-methyl ether (6), cystodione A (7), and cystodione B (8) (Figure 1) isolated from the 
alga C. usneoides have been investigated for their anti-inflammatory and anticancer activities. 
2.1. Anti-Inflammatory Activity 
2.1.1. Effects of AMTs 1–8 on the Viability of THP-1 Cells 
The cytotoxic effect of AMTs 1–8 on LPS-stimulated THP-1 macrophages was determined at 
different concentrations and incubation times (0–100 µg/mL, 48 and 72 h) using the SRB assay. The 
results of this analysis demonstrated that none of the molecules affect cell viability at concentrations 
up to 10 µg/mL for AMTs 1, 2, 3, 4, 7, 8, and up to 6 µg/mL for AMTs 5 and 6 (data not shown). 
Therefore, in order to rule out cytotoxic effects, compounds 1, 2, 3, 4, 7, and 8 were tested on THP-1 
cells at maximum concentration of 8 µg/mL while 5 and 6 were tested at maximum concentration of 
4 µg/mL. 
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Figure 1. Chemical structures of the meroterpenes from C. usneoides subjected to anti-inflammatory 
and lung anticancer studies: usneoidone Z (1), 11-hydroxy-1′-O-methylamentadione (2), 
cystomexicone B (3), cystomexicone A (4), 6-cis-amentadione-1′-methyl ether (5), 
amentadione-1′-methyl ether (6), cystodione A (7), and cystodione B (8). 
2.1.2. Effects of AMTs 1–8 on TNF-α, IL-6, and IL-1β Expression in LPS-stimulated THP-1 
Macrophages 
To determine the effects of the AMTs 1–8 on the production of TNF-α, IL-6, and IL-1β, THP-1 
macrophaghes were pretreated with the compounds and then stimulated with LPS, as the triggering 
factor to stimulate the cytokines production. The levels of pro-inflammatory cytokines in the cell 
supernatants were determined using the enzyme-linked immunosorbent (ELISA) kits. Upon 
comparison with the control cells, TNF-α, IL-6, and IL-1β levels were significantly increased in LPS 
stimulated cells up to 282.06, 389.47, and 181.80 ng/mL, respectively (Figure 2). 
However, LPS-stimulated THP-1 macrophages pre-treated with the AMTs 1–8 showed a 
significant reduction of the production of pro-inflammatory cytokines (Figure 2). Regarding TNF-α, 
although all compounds induced a significant reduction of the level of this cytokine in THP-1 
(Figure 2A), the meroditerpenes 1 and 2 showed the higher suppressive effect causing 73.11% and 
64.14% inhibition. Compounds 3, 5, and 8 also induced more than 50% of inhibition (57.13%, 55.34%, 
and 52.56%, respectively), while compounds 4, 6, and 7 were less active, reducing the production of 
TNF-α between 42.18 and 43.32% (p < 0.01). As shown in Figure 2B, among the eight AMTs, 
compound 2 markedly inhibited LPS-induced IL-6 production in THP-1 macrophages by 80.81% 
and compounds 1, 3, and 5 caused strong inhibitions of 71.20%, 69.18% and 67.83%, respectively. The 
treatment of cells with compounds 4, 6, 7, and 8 also significantly inhibited the production of IL-6 
upon comparison with LPS-stimulated THP-1 control cells, although to a lesser extent (43.00%, 
50.94%, 49.57% and 58.87%, respectively). With regard to IL-1β production, the pretreatment of cells 
with the AMTs 1–8 resulted in significant inhibition of this cytokine (Figure 2C). The most marked 
effects were observed in the cells treated with compounds 2 and 5, which blocked the effect of 1 
µg/mL LPS by 84.43% and 86.00%, respectively. Moreover, pretreatment with the AMTs 1 and 6 also 
strongly inhibited LPS-induced IL-1β production by 74.56% and 61.07%, respectively. The AMTs 3, 
7, and 8 displayed more moderated inhibitory activity, causing IL-β decreases of 35.28%, 44.85%, 
and 44.60%, respectively. 
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Figure 2. Meroterpenoids 1–8 inhibit LPS-induced expression of TNF-α, IL-6, and IL-1β in THP-1 
macrophages (A, B, and C) respectively. Cells were pretreated for 1 h with the compounds (1, 2, 3, 4, 
7, and 8 at 8 µg/mL; 5 and 6 at 4 µg/mL), followed by 24 h treatment with LPS. TNF-α (A), IL-6 (B) 
and IL-1β (C) contents in the culture medium were determined by ELISA. Dexametasone (DEX) was 
used as positive control. Data are expressed as means ± SE from three independent experiments. 
Statistical significance is indicated (+++p < 0.001 and +++< 0.01 vs. Control; respectively * p < 0.05, ** p 
< 0.01, *** p < 0.001 vs. Control + LPS). 
2.1.3. Effects of AMTs 1–8 on the Expression of COX-2 and iNOS Proteins in LPS-stimulated THP-1 
Cells 
COX-2 is the key enzyme regulating the production of prostaglandins, which are the central 
mediators of inflammation. On the other hand, iNOS enzyme represents an important molecular 
target closely involved in inflammatory responses. Thus, the effect of the AMTs 1–8 on LPS-induced 
COX-2 and iNOS protein expression was investigated by western blot analysis. As shown in Figure 
3, the expression of COX-2 and iNOS proteins was markedly augmented in THP-1 macrophages 
upon LPS treatment. The pretreatment with the AMTs 2, 3, 4, 5, 6, and 7 significantly 
down-regulated the expression of COX-2, while no significant effect was observed for compounds 1 
and 8. The more active compounds were 3, 5, 6, and 7, which decreased COX-2 levels by 53.35%, 
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53.52%, 64.23%, and 58.05% respectively. On the other hand, AMTs 1–8 effectively suppressed 
LPS-induced iNOS expression, decreasing iNOS levels in the range 40.31%–54.93%. 
 
Figure 3. Effect of meroterpenoids 1–8 on LPS-induced COX-2 and iNOS protein expression in 
THP-1 macrophages. Cells were pretreated for 1 h with the compounds (1, 2, 3, 4, 7, and 8 at 8 µg/mL; 
5 and 6 at 4 µg/mL) and then stimulated with LPS (1 µg/mL). Cytosolic lysates from 24 h-stimulated 
cells were separated on 10% SDS-PAGE. COX-2, iNOS, and β-actin were detected by western blot 
analysis. Data are expressed as means ± SE from three independent experiments. Statistical 
significance is indicated (+++ p < 0.001 and ++ p < 0.01, vs. Control, respectively; * p < 0.05, and ** p < 
0.01 vs. Control + LPS). 
2.2. Anticancer Activity 
2.2.1. Cytotoxic Effects and Selectivity of the AMTs 1–8 
The effect of the AMTs 1–8 on cell viability was investigated in the human lung cancer cell line 
A549. The results (Figure 4) indicated that all the AMTs inhibited the A549 cell growth after 72 h of 
incubation in a dose-dependent manner. The most active compounds were 1, 2, 5, and 6 with IC50 
values of 8.68, 6.61, 4.56, and 6.19 µg/mL, respectively (Table 1). Since the AMTs 1–8 showed an 
interesting cytotoxic activity towards A549 cells, the compounds were similarly evaluated on a 
normal cell line (human fetal lung fibroblastic MRC-5 cells) to determine the selectivity index (SI = 
IC50 value for normal cells / IC50 value for cancer cells). It has been reported that compounds with SI 
value higher or equal to 2.0 are potentially selective [34]. According to the data in Table 1, all AMTs 
showed selective cytotoxicity against the cancer cells; especially compounds 3 and 4, which at 
increasing concentrations maintained higher toxicity against A549 cancer cells than against MRC-5 
non-malignant cells (Figure 4). It is worth noting that after treatment with 50 µg/mL of these two 
AMTs, the cell viability was lower than 15% for cancer cells and higher than 55% for normal cells. On 
the other hand, 1 was the less selective compound; its SI was 1.22. 
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Figure 4. Effects of different concentrations of meroterpenoids 1–8 on the viability of human lung 
cancer cell line A549 and the human fetal lung fibroblastic MRC-5 cells, using MTT assay after 72 h of 
treatment. Data are mean ±SE of three independent experiments. * p < 0.05, ** p < 0.01 and *** p < 0.01 
between the two cell lines. 
Table 1. IC50 values (µg/mL) of meroterpenoids 1–8 against the normal lung cells MRC-5 and the 
lung cancer cells A549, after 72 h of treatment. SI = IC50 value for normal cells/IC50 value for cancer 
cells. 
Compound 
Cell Lines Selectivity Index  
MRC-5 A549 SI 
1 10.64 ± 0.50 8.68 ± 0.15 1.22 
2 8.65 ± 0.18 6.61 ± 0.38 1.30 
3 51.91 ± 2.76 24.42 ± 1.71 2.12 
4 58.38 ± 3.30 21.00 ± 1.79 2.78 
5 8.39 ± 0.14 4.56 ± 0.21 1.83 
6 8.87 ± 0.05 6.19 ± 0.25 1.43 
7 14.46 ± 1.14 9.31 ± 0.33 1.55 
8 17.83 ± 0.09 13.6 ± 0.55 1.28 
Data are means ± SE from three independent experiments. 
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2.2.2. Effects of AMTs 1–8 on A549 Cell Cycle Progression 
We next investigated whether the treatment with AMTs 1–8 caused any cell cycle-related event, 
which inhibit the viability of A549 cell line. Thus, the cells were treated for 24 h with the AMTs at 
concentrations of IC50 (Table 1), or with colchicine (at 0.2 µg/mL) as the positive control, and then 
subjected to flow cytometry analysis to evaluate the distribution of cells in the different phases of the 
cell cycle (Figure 5A). The results showed that most of the AMTs assayed induced a significant 
accumulation of cells at the G2/M phase (20.20%–40.19%) and at the S phase (9.73%–17.91%) of the 
cell cycle, with a parallel depletion of the percentage of cells in G0/G1 phase (49.31%–65.43%), while 
colchicine arrested 89.88% of cells in G2/M phase. The AMTs 1, 2, 7, and 8 were the most active and 
caused a remarkably increase of cells at G2/M phase (31.15%, 31.62%, 40.19%, and 32.50%, p < 0.01, 
respectively) compared with the control group (14.06%), and at S phase (17.75%, 17.90%, 13.69%, and 
16.73%, p < 0.01, respectively) compared with the control group (4.99%). In parallel, a decrease of the 
population at G0/G1 phase was observed in the cells treated with these compounds (64.52%, 65.42%, 
49.31%, p < 0.01 and 61.29%, p < 0.05, respectively) in comparison with the control group (71.40%) 
(Figure 5B). 
 
Figure 5. Effects of meroterpenoids 1–8 on cell cycle distribution of A549 cells. Cells were incubated 
with IC50 doses of the compounds for 24 h. (A) Cells were harvested to measure the cell cycle 
distribution by flow cytometry. (B) Quantitative analysis of cell cycle distribution after treatment. 
Data represent mean ±SE from three independent experiments. * p < 0.05, ** p < 0.01, and *** p < 0.001 
compared with the untreated group (control). 
Control Colchicine
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3. Discussion 
In the present study, we have expanded the knowledge about the in vitro anti-inflammatory 
and anticancer activities of eight AMTs (1–8) isolated from the brown alga C. usneoides [33]. 
First, we investigated the anti-inflammatory effects of the AMTs 1–8 and their molecular 
mechanisms in LPS-induced THP-1 macrophages. The production of pro-inflammatory mediators 
including TNF-α, IL-6, and IL-1β by macrophages exposed to endotoxins is well established [35,36]. 
TNF-α plays a major role in initiating and regulating the release of adhesion molecules and the 
expression of inflammatory mediators during inflammatory responses [37]. IL-6 is a multifunctional 
cytokine that plays a role in inflammatory responses through the stimulation of acute phase 
responses, hematopoiesis, and immune reactions [38]. Moreover, inhibition of IL-6 signaling has 
been successfully translated into the clinic as a powerful anti-inflammatory strategy [39]. IL-1β is 
one of the most potent pro-inflammatory cytokines, which affects a large number of cellular 
responses and mediates inflammatory processes at local and systemic levels [40,41]. These 
pro-inflammatory mediators can induce cell and tissue damage and also activate macrophages in 
various inflammation-associated diseases [42]. The protein COX-2 is an important inflammatory 
enzyme responsible for the high prostaglandin levels widely observed in inflammatory pathology 
[43]. The enzyme iNOS is greatly expressed in macrophages and its activation leads to organ 
destruction in some inflammatory and autoimmune diseases [44]. Therefore, treatments aimed to 
suppressing pro-inflammatory cytokines and enzymes are regarded an effective therapeutic strategy 
for the control of several disorders, including inflammatory diseases. 
In this study, we found that the AMTs 1–8 significantly reduced the secretion of the 
pro-inflammatory cytokines TNF-α, IL-6, and IL-1β, as well as inhibited the expressions of proteins 
COX-2 and iNOS in LPS-induced THP-1 macrophages. These findings are in line with previous 
results from our group showing that other related AMTs reduce TNF-α expression in 
LPS-stimulated THP-1 cells [45]. Moreover, the results obtained for the AMTs 1–8 represent the first 
account on the activity of this class of meroterpenoids as inhibitors of the pro-inflammatory 
mediators IL-6, IL-1ß, COX-2 and iNOS. Overall, the AMTs 1 and 2 were the most potent inhibitors 
of the production of the three pro-inflammatory cytokines, causing decreases in the range 71.20%–
84.43% at 8 µg/mL; at this concentration, compound 2 also significantly inhibited COX-2 and iNOS. 
The inhibitory effects observed for this molecule (compound 2, also 
11-hydroxy-1′-O-methylamentadione or AMT-E) on THP-1 cells are consistent with the in vivo 
study described in our previous report, which showed exerting intestinal anti-inflammatory activity 
in colitis by down-regulating TNF-α, IL-1ß, and IL-10, as well as suppressing COX-2 and iNOS 
expression in the mouse colon tissue [46]. 
Recent reports have also demonstrated the anti-inflammatory potential of a variety of algal 
terpenes and meroterpenes [23]. A number of compounds have been assayed on LPS-stimulated 
RAW264.7 macrophages [47–49]. Thus, the diterpenoid nerogioltriol from the red alga Laurencia 
glandulifera was found to inhibit the activation of NF𝜅B and the production of NO, TNF-𝛼, and 
COX-2 [47], while the sesquiterpene 5β-hydroxypalisadin B from L. snackeyi [48] and the 
meroterpene sargachromanol G from Sargassum siliquastrum [49] were shown to inhibit the 
production of NO, TNF-𝛼, IL-6, and IL-1β, as well as to reduce the COX-2 and iNOS expression in 
LPS-stimulated RAW264.7 macrophages. Other terpenes from Dictyota plectens showed 
anti-inflammatory effects by inhibiting the LPS-induced NO production in mouse peritoneal 
macrophages [50]. Recently, several halogenated sesquiterpenoids from the red alga Laurencia 
tristicha and meroterpenoids from the brown alga Homoeostrichus formosana, also showed an 
interesting anti-inflammatory ability by inhibiting the N-formylmethionyl-leucyl-phenylalanine 
cytochalasin B (fMLP/CB)-induced superoxide anion (O2−•) generation and elastase release in human 
neutrophils [51,52]. The results obtained in our study of the effects of the AMTs 1–8 on 
LPS-stimulated THP-1 macrophages are in line with the anti-inflammatory activities described 
above. Because these inflammatory mediators have an important role during carcinogenesis and 
they are secreted by M1 macrophages and other immune cells, terpenoids from C. usneoides may 
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have the potential to prevent carcinogenesis. Further research is needed to elucidate the 
anti-inflammatory potential of these compounds. 
We next investigated the effects of the AMTs 1–8 on the viability of the lung cancer cells A549. It 
is well known that chronic inflammation is associated with several chronic diseases including cancer 
[53,54]. Cancer is the second leading cause of death worldwide, with lung cancer recognized as one 
of the most mortal cancer types (OMS, 2018). The metastatic cancer is an incurable disease for most 
patients because the current anticancer therapies lack enough selective cytotoxicity to kill cancer 
cells without affecting healthy tissues [55]. Therefore, the development of new drugs with higher 
selectivity towards cancer cells is vital to advance towards the cure to this deadly disease. Nature 
has provided useful anticancer drugs (e.g., the vinca alkaloids and the diterpene taxol)—and it is still 
a source of new agents [56]. In this line, along the last decades, an array of new anticancer 
compounds has also been isolated from marine organisms [57]. 
In this study, we have shown the anticancer activity of eight AMTs obtained from the alga C. 
usneoides. In particular, we studied the cytotoxicity of the AMTs 1–8 against lung cancer cells and 
lung normal cells. All AMTs significantly inhibited the survival of A549 cancer cells. Interestingly, 
the compounds exhibiting a chain of 20 carbon atoms (1, 2, 5–8) were more cytotoxic (IC50 ranging 
from 4.56 to 13.96 µg/mL) than those with a chain of 14 carbon atoms (3 and 4). Moreover, we found 
that the cancer cells were more sensitive to the cytotoxic effect of AMTs 1–8 than MRC-5 normal 
cells. Compounds 3 and 4 had the highest selectivity towards cancer cells, showing selective 
cytotoxic activity at several concentrations assayed (from 12 to 50 µg/mL). Among algae-derived 
metabolites, a few terpenoids and meroterpenoids have also been recently reported to possess 
anticancer activity against lung cancer cells A549; thus the sesquiterpenes elatol from Laurencia 
microcladia together with 5β-hydroxyaplysin and its hydroperoxy analogue from L. okamurai had 
cytotoxic effects towards A549 human cancer cell line with IC50 values of 4.8, 35.3, and 15.4 µM, 
respectively [58,59], while the diterpenes sphaerococcenol A, and two related analogues from 
Sphaaerococcus coronopifolius, inhibited the growth of A549 cells with IC50 values of 3.7, 19.0, and 18.0 
µM, respectively [60]. Likewise, meroditerpenoids from algae of the genus Callophycus exhibited 
cytotoxicity towards several human cancer cell lines, including A549 cells, with the higher activity 
observed for bromophycolides M, N, O, P, Q and bromophycoic acid D (mean IC50 values of 3.1, 8.6, 
9.7, 7.9, 2.0, and 6.8 µM, respectively) [61,62]. In view of these data from the literature, the activity of 
AMTs 1, 2, and 5–8 against A549 cells is comparable with several of the values described above. 
We have also demonstrated that most of the AMTs suppress the proliferation of A549 by 
arresting the cell cycle progression at the G2/M and S phases. The cell cycle checkpoints play a key 
role in the machinery that controls cell division by sensing defects occurring in vital processes, such 
as DNA replication or chromosome segregation, inducing a cell cycle arrest until the repair of the 
detected defects [63]. The effect of algal terpenes on lung cancer and cell cycle distribution has been 
scarcely documented, and less in A549 cells. A report on the sesquiterpene elatol, isolated from 
Laurencia microcladia [58], showed anticancer properties by inducing cell cycle arrest in the G1 and 
the sub-G1 phases in several human cancer cell lines, including A549 cell line. Our results suggest, 
for the first time, that the meroterpenoids 1–8 affect the molecular pathways that control the A549 
cell cycle progression by arresting the cells at the G2/M and S checkpoints. 
4. Materials and Methods  
4.1. Isolation and Characterization of Meroterpenoids 1–8 
The collection of the alga samples, preparation of the extract, purification and structural 
characterization of the meroterpenoids 1–8 was performed, as previously described [33]. Briefly, 
shade-dried samples of C. usneoides collected at the Gibraltar Strait were ground and extracted with 
acetone/methanol (MeOH). The resulting extract was subjected to column chromatography (CC) on 
silica gel (Merck KGaA, Darmstadt, Germany) eluting with n-hexane/diethyl ether (Et2O) mixtures 
of increasing polarity, then Et2O, chloroform/MeOH mixtures, and finally MeOH. The fractions 
eluted with n-hexane /Et2O (30:70, v/v), Et2O, and chloroform/MeOH (95:5, v/v) were subjected to CC 
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on silica gel (Merck) using n-hexane/ethyl acetate (EtOAc) mixtures as eluents. Further separation of 
selected subfractions by normal phase HPLC using n-hexane/EtOAc (60:40 and 50:50, v/v) or 
n-hexane/isopropanol (90/10, v/v) as eluents led to obtain compounds 1–8. HPLC separations were 
performed on a LaChrom-Hitachi apparatus (Merck), equipped with LiChrospher Si-60 (250 × 10 
mm, 10 µm) (Merck) and Luna Si (2) (250 × 4.6 mm, 5 µm) (Phenomenex, Torrance, CA, USA) 
columns, using an RI-71 differential refractometer or L-7400 UV detector (Merck). The isolated 
compounds were identified by using nuclear magnetic resonance (NMR) and mass spectrometry 
(MS). NMR spectra were recorded on an Agilent 500 spectrometer (Agilent Technologies, Santa 
Clara, CA, USA) using CD3OD or CDCl3 (Sigma-Aldrich, St. Louis, MO, USA) as solvent. MS spectra 
were obtained on a Waters SYNAPT G2 spectrometer (Waters, Milford, MA, USA). Fully assigned 
spectroscopic data of the isolated compounds can be found in our previous paper [33]. 
4.2. Reagents for Anti-Inflammatory and Anticancer Assays 
Sulforhodamine B (SRB), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide salt 
(MTT), dimethylsulfoxide (DMSO), Propidium Iodide (PI), Tris-base, acetic acid, trichloroacetic acid 
(TCA), colchicine and RNase were from Sigma-Aldrich (Munich, Germany); RPMI 1640 medium 
and fetal bovine serum (FBS) were from GIBCO (Grand Island, NY, USA); phosphate buffer saline 
(PBS), streptomycine, penicillin, and trypsine-EDTA were from PAA Laboratories (Pasching, 
Austria). Phorbol myristate acetate (PMA) was from Sigma-Aldrich Química (Madrid, Spain). For 
western blotting, anti-COX-2 (Cayman Chemical®, Ann Arbor, MI, USA), anti-iNOS (Stressgen-Enzo 
Life Sciences, Farmingdale, NY, USA), anti-rabbit IgG antibody (Dako® Cytomation, Carpinteria, 
CA, USA), anti-β-actin (Santa Cruz Biotechnology, Dallas, TX, USA) were purchased. 
4.3. Anti-Inflammatory Assays 
4.3.1. Cell Culture 
THP-1 human monocytic leukemia cell line was obtained from the American Type Culture 
Collection (TIB-202, ATCC, Manassas, VA, USA). The cells were cultured in RPMI 1640 medium 
containing 10% heat-inactivated FBS, 100 U/mL penicillin, and 100 mg/mL streptomycin, at 37 °C in 
humidified air containing 5% CO2. 
4.3.2. Cell Viability Assay 
The viability of THP-1 cells was measured by the SRB assay [64]. The cells were seeded in 
96-well plates with the growth medium at a density of 1 × 104 cells per well, and differentiation into 
macrophages was induced by 0.2 µM of phorbol myristate acetate (PMA) [65]. Three days after 
differentiation into macrophages, the cells were treated with various concentrations (0, 3.125, 6.25, 
12.5, 25, 50, 100 µg/mL) of the AMTs 1–8 in fresh medium and incubated for another 72 h. Then, the 
cells were fixed with 50 µL of TCA (50%) and processed, as described in the literature [64]. 
4.3.3. Determination of Pro-Inflammatory Cytokines Production 
THP-1 cells were plated at a density of 3 × 105 cells/mL in 24-well plates and incubated with 
PMA (0.2 µM) for 72 h in a humidified atmosphere of 5% CO2 at 37 °C. The macrophages were 
pre-treated for 1 h with AMTs 1–8 (8 µg/mL for compounds 1, 2, 3, 4, 7, and 8, and 4 µg/mL for 5 and 
6) and then stimulated with lipopolysaccharide (LPS, 1 µg/mL) for another 24 h. Dexamethasone 
(Dex) was used as positive reference compound at 1 µM. The viability of cells was greater than 95% 
throughout the experiment. The levels of TNF-α, IL-6, and IL-1ß in supernatants were measured 
with enzyme-linked immune-sorbent assay (ELISA) kits (Diaclone GEN-PROBE, Besançon cedex, 
France) according to the manufacturer’s protocols. The absorbance was determined at 450 nm using 
a microplate reader. To calculate the concentration of cytokines, a standard curve was constructed 
using serial dilutions of cytokine standards provided with the kit. 
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4.3.4. Western Blotting Analysis 
Western blotting was used to measure the protein levels of COX-2 and iNOS [65]. THP-1 
macrophages were plated at a density of 1 × 106 cells/mL in six-well plates, treated for 1 h with 
compounds 1–8 (8 µg/mL for compounds 1, 2, 3, 4, 7, and 8, and 4 µg/mL for compounds 5 and 6), 
and then stimulated with 1 µg/mL of LPS in medium at 37 °C. After 24 h, the cells were washed with 
ice-cold PBS, collected, suspended in the lysis buffer (250 mM NaCl, 50 mM Tris (pH 7.5), 0.5 mM 
EDTA, 5 mM EGTA, 8 mM MgCl2, 1 mM PMSF, 0.01 mg/mL pepstatin A, 0.01 mg/mL leupeptin, 
0.01 mg/mL aprotinin, 1% Triton X-100) and centrifuged at 12,000g at 4 °C for 3 min to yield cell 
lysates. Proteins concentration in cell lysates was determined by Bio-Rad Protein Assay, based on 
the method of Bradford (BioRad, Richmond CA, USA) [66]. Cytosolic proteins (50 µg) were 
separated with 10% SDS-polyacrylamide gel electrophoresis and transferred on PVDF membranes. 
The membranes were then blocked with 5% (w/v) non-fat dry milk in Tris-buffered saline containing 
0.1% Tween-20 (pH 7.4) (TBST) buffer at room temperature for 1 h. The membranes were washed 
three times (10 min) in TBST buffer and incubated with specific primary antibodies anti-COX-2 
(1:3000) or anti-iNOS (1:1000) diluted in 5% (w/v) non-fat dry milk in TBST buffer, at 4 °C overnight. 
Then, the membranes were incubated with peroxidase-conjugated bovine peroxidase-conjugated 
goat anti-rabbit IgG (1: 1000) for 1 h at room temperature. To ascertain that blots were loaded with 
equal amounts of protein lysates, they were also incubated in the presence of the antibody against 
β-actin protein (1:10,000). After washing the membrane again with TBST buffer (10 min) three times, 
the antibody was visualized using an enhanced chemiluminescence light-detecting kit (Super-Signal 
West Pico Chemiluminescent Substrate, Pierce, IL, USA), according to the manufacturer’s 
instructions and exposed to an X-ray film (GE Healthcare Ltd., Amersham, UK). The protein band 
densities were quantified using a Scientific Imaging Systems (Biophotonics ImageJ Analysis 
Software, National Institute of Mental Health, Bethesda, MD, USA). 
4.4. Anticancer Assays 
4.4.1. Cell Line and Cell Culture  
The human fetal lung fibroblastic MRC-5 cell line and the human lung adenocarcinoma A549 
cell line were obtained from European Collection of Cell Cultures and maintained in Dulbecco’s 
Modified Eagle’s Medium (DMEM) supplemented with 2 mM glutamine, 100 U/mL penicillin, 100 
µg/mL streptomycin and 10% FBS. Cell lines were cultured at 37 °C in a humidified atmosphere 
containing 5% CO2. 
4.4.2. Cytotoxicity Test 
Cell proliferation was evaluated by a modified MTT assay, which measures the mitochondrial 
dehydrogenase activity [67]. A total of 5 × 103 cells/well (MRC-5 cells) and 3 × 103 cells/well (A549 
cells) were cultured in a 96-well plate for 24 h. Then, treatments were added to the cell culture. After 
72 h of incubation, the medium was removed and 125 µL of MTT (1 mg/mL in medium) was added 
to each well and incubated for 4 h. Next, 80 µL of 20% sodium dodecyl sulphate (SDS) was added 
and incubated for 5 h at 37 °C. The optical density of each well was measured at 540 nm (Synergy HT 
multiwell plate spectrophotometer reader, BioTek Instruments Inc., Winooski, VT, USA) to quantify 
cell viability. Cell viability (%) was calculated according to the following formula: % viability = 
(absorbance of compounds treated cells/absorbance of control cells) × 100. The degree of selectivity 
of the compounds was expressed by its SI value. Each SI value was calculated using the formula: SI = 
IC50 normal cell/IC50 cancer cell. 
4.4.3. Cell Cycle Analysis 
For cell cycle analysis by flow cytometry, A549 cells were seeded at 1 × 106 cells/well in 6-well 
plates and incubated for 24 h followed by treatment with the AMTs, at concentration of IC50, and 
further incubation for 24 h. Colchicine (final concentration of 0.2 µg/mL) was used as positive 
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control. Cells were harvested after trypsinization and washed once with PBS. Then, the cells were 
centrifuged at 1500 rpm for 5 min (25 °C), the pellet was fixed with 1 mL of ice-cold 70% ethanol, and 
the samples were stored at −4 °C overnight. Then the cells were washed with PBS and incubated in 
the darkness with PBS containing 5 mg/mL of RNase A for 48 h at 4 °C. Subsequently, 50 µL of 
propidium iodide (0.1 mg/mL) was added and the cells were incubated for 1 h at 4 °C. The relative 
DNA content per cell was analyzed using a Beckman Coulter Cytomics FC 500 MPL (Beckman 
Coulter Inc, San Diego, CA, USA). The data acquisition was performed with the DML program. The 
analysis of the acquired data was performed with the CXP cytometer. 
4.4.4. Statistical Analysis 
The results are presented as the mean ± Standard Error (SE) of at least three independent 
experiments. Data were evaluated with GraphPad Prism® Version 5.00 software (San Diego, CA, 
USA). Differences between two groups were analyzed by the Student’s t-test. Difference with p < 
0.05 (*), p < 0.01 (**) or p < 0.001 (***) were considered statistically significant. The cytotoxic activity of 
a drug was determined against two cell lines; the statistical analysis was carried out to compare the 
cytotoxicity of a particular concentration of the compound between both cell lines. 
5. Conclusions 
Various AMTs significantly reduced the secretion of the pro-inflammatory cytokines and 
inhibited the expressions of proteins COX-2 and iNOS in THP-1 activated macrophages. Likewise, 
most of the AMTs suppressed the proliferation of A549 lung cancer cells by arresting cell cycle 
progression at the G2/M and S phases. 
Because these inflammatory mediators have an important role during carcinogenesis and they 
are secreted by M1 macrophages and other immune cells, the present results do allow selecting 
meroterpenoids from C. usneoides for future approaches to in vitro and in vivo models of inhibiting 
inflammation to prevent carcinogenesis. Upcoming experiments in this field are guaranteed. 
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